The estimated Net Worth of Michael Alfieri is at least $0 dollars as of 13 September 2018. Michael Alfieri owns over 10,000 units of Genocea Biosciences Inc stock worth over $0 and over the last 6 years Michael sold GNCA stock worth over $0.
Michael has made over 1 trades of the Genocea Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Michael bought 10,000 units of GNCA stock worth $5,400 on 13 September 2018.
The largest trade Michael's ever made was buying 10,000 units of Genocea Biosciences Inc stock on 13 September 2018 worth over $5,400. On average, Michael trades about 5,000 units every 0 days since 2018. As of 13 September 2018 Michael still owns at least 10,000 units of Genocea Biosciences Inc stock.
You can see the complete history of Michael Alfieri stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA.
Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell oraz Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Genocea Biosciences Inc executives and other stock owners filed with the SEC include: